Tagomics Ltd., a pioneering biomarker discovery and diagnostics firm, at this time introduced it has entered right into a strategic co-marketing settlement with Agilent Applied sciences, a number one instruments supplier within the genomics sector. The settlement gives choose prospects the chance to entry Tagomics’ and Agilent Applied sciences’ mixed modern choices by an unique expertise entry program hosted out of Tagomics’ service lab in Cambridge.
Tagomics has developed a novel multiomics platform, InterlaceTM, that unlocks disease-associated DNA biomarkers from a variety of organic sources. Its expertise leverages a novel method to epigenetic profiling which particularly enriches unmethylated DNA for evaluation, with out modifying the underlying DNA sequence. The Interlace platform seamlessly integrates complete genome sequencing or focused sequencing, and mixed with its superior bioinformatics and machine studying software program, allows the evaluation of epigenetic, genetic, and fragmentomic options in a single, cost-effective, low-input, and automatable workflow.
Agilent Applied sciences offers complete options for focused genomic profiling. The SureSelect Library Preparation and Goal Enrichment System, mixed with the SureSelect Most cancers panels, allows environment friendly detection of a wide selection of somatic variants in stable tumors, together with single nucleotide variants (SNVs), copy quantity variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability).
Tagomics has seamlessly built-in Agilent’s SureSelect XT HS2 Library Preparation and Goal Enrichment System into its multiomic workflow. This mixture allows complete genomic and epigenomic insights, all inside a single, unified workflow.
To showcase the potential of this mixed method, Tagomics has signed a co-marketing settlement with Agilent Applied sciences, and launched a expertise entry program which permits choose prospects to expertise the improved capabilities of the mixed platform forward of the broader market. Clients will profit from extra complete insights into the mechanisms driving illness, opening the door to novel diagnostic and therapeutic methods.
We’re happy to be working with Agilent Applied sciences to convey choose prospects the mixed capabilities of our respective platforms, unified in Tagomics’ Interlace multiomic workflow. By way of this collaboration, we stay up for empowering prospects with deeper organic insights and accelerating the event of modern diagnostic and therapeutic options.”
Dr Jack Kennefick, CEO and co-founder, Tagomics
Ronda Allen, normal supervisor of Genomics at Agilent Applied sciences commented: “By way of our settlement, our prospects could have entry to Tagomics’ Interlace platform and superior bioinformatics software program, enabling simultaneous genetic and genome-wide epigenomic profiling. Incorporation of our SureSelect Library Preparation and Goal Enrichment System into Tagomics’ workflow enhances our established capabilities in genomic profiling, furthering our mission to convey nice science to life.”
